Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML
Annals of Hematology · 19.08.2026 · 105 (12)
DOI: 10.1007/s00277-026-07222-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 19.08.2026. Verfasst von Junqing Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Decitabine, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The combination of hypomethylating agents and venetoclax (VEN) has emerged as a new standard of care for elderly or unfit patients. In this study, we conducted a retrospective analysis of 37 patients with acute myeloid leukemia (AML) to investigate the efficacy and safety of a low‑dose 10‑day decitabine (DEC) combined with venetoclax (VEN) regimen (DEC 6 mg/m 2 for 10 days and VEN for 14 days). The composite complete remission (CRc) rate was 78.4%, with 88.9% in favorable group and 75.0% in intermediate/adverse group according to ELN-2022 risk stratification. Among patients who achieved CRc, 79.3% patients attained MRD negativity after the first cycle. With a median follow-up of 40.0 months, the median overall survival (OS) was 36.1 months. The 36-month OS and EFS rates were 35.0% and 40.4%. Hematologic toxicities were the most common adverse events. The multivariate analysis showed that patients with ECOG < 3 and non-complex karyotype had significantly better OS. The regimen of low-dose 10-day DEC plus VEN induced rapid MRD negativity with good tolerability, along with high long-term survival in patient ineligible for intensive therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. zhengwy2006@zju.edu.cn.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. zhengwy2006@zju.edu.cn.
Zitieren
APA
Wu, J., Luo, X., Liu, X., Li, J., Fu, S., Huang, H., & Zheng, W. (2026). Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML. Annals of Hematology, 105(12). https://doi.org/10.1007/s00277-026-07222-7
Vancouver
Wu J, Luo X, Liu X, Li J, Fu S, Huang H, et al. Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML. Annals of Hematology. 2026;105(12). doi:10.1007/s00277-026-07222-7
BibTeX
@article{Wu2026,
author = {Wu, Junqing and Luo, Xueping and Liu, Xiaoyu and Li, Jingwen and Fu, Shan and Huang, He and Zheng, Weiyan},
title = {Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in De Novo AML},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {12},
doi = {10.1007/s00277-026-07222-7}
}
EUVIMED